Beijing Tian Yuan Law Firm
Supplementary Legal Opinion (I) on Beijing Tian Yuan Law Firm's Supplementary Legal Opinion on Jiangsu Dongxing Smart Medical Technology Co., Ltd.'s Cash Purchase of Assets
To: Jiangsu Dongxing Smart Medical Technology Co., Ltd.
Jing Tian Gu Zi (2026) No. 167-1
Beijing Tian Yuan Law Firm has been retained by Jiangsu Dongxing Smart Medical Technology Co., Ltd. (hereinafter referred to as the "Company") to act as its legal advisor for the cash purchase of assets transaction (hereinafter referred to as the "Transaction") and to issue a legal opinion.
The Firm and the handling lawyers, in accordance with the Company Law, the Securities Law, the Administrative Measures for the Practice of Securities Legal Business by Law Firms, the Practice Rules for Securities Legal Business of Law Firms (Trial), and other laws, regulations, and normative documents, as well as the relevant regulations of the China Securities Regulatory Commission, have issued the "Beijing Tian Yuan Law Firm's Legal Opinion on Jiangsu Dongxing Smart Medical Technology Co., Ltd.'s Cash Purchase of Assets" (hereinafter referred to as the "Legal Opinion"), Jing Tian Gu Zi (2026) No. 167.
This Supplementary Legal Opinion is issued due to changes in the circumstances related to the Transaction from the date of the Legal Opinion to the date of this Supplementary Legal Opinion.
This Supplementary Legal Opinion supplements the Legal Opinion and forms an integral part of the Legal Opinion. The premises and declarations made in the Legal Opinion apply to this Supplementary Legal Opinion. Unless otherwise specified, the definitions of terms in this Supplementary Legal Opinion are the same as those in the Legal Opinion. In case of any inconsistency between the Legal Opinion and this Supplementary Legal Opinion, this Supplementary Legal Opinion shall prevail.
This Supplementary Legal Opinion is for the purpose of the Company's Transaction only. Without the written consent of the Firm, it shall not be used for any other purpose. The Firm agrees that this Supplementary Legal Opinion may be used as a required legal document for the Transaction application and will be submitted together with other application materials, and the Firm will bear the corresponding legal responsibilities.
Based on the foregoing, the Firm and the handling lawyers, in accordance with relevant laws and regulations, and in accordance with the industry-recognized professional standards, ethical norms, and diligent and responsible spirit of the legal profession, hereby issue this Supplementary Legal Opinion.
2
Main Text
I. Approval and Authorization of the Transaction
(I) Approvals and Authorizations Obtained Since the Issuance of the "Legal Opinion"
1. Approvals and Authorizations Newly Obtained by Dongxing Medical
On June 12, 2026, Dongxing Medical held its 17th meeting of the Fourth Board of Directors, which reviewed and approved the "Proposal on Adjusting the Company's Major Asset Reorganization Transaction Plan," the "Proposal on the 'Report on the Major Asset Purchase of Jiangsu Dongxing Smart Medical Technology Co., Ltd. (Draft) (Revised Draft)' and its Summary," and the "Proposal on the Supplementary Agreement to the Transaction Agreement." It was also decided to convene the first interim shareholders' meeting of 2026 to review matters related to the Transaction.
2. Approvals and Authorizations Newly Obtained by the Transaction Counterparty
On June 2, 2026, Tianhui Technology passed a resolution at its shareholders' meeting, agreeing to sign the "Supplementary Agreement to the Equity Acquisition Agreement of Wuhan Yijia Bao Biotechnology Materials Co., Ltd." with other transaction parties.
(II) Approvals and Authorizations Still Required for the Transaction
In accordance with the Measures for the Administration of Major Asset Reorganizations and other relevant laws, regulations, and normative documents, the Transaction still requires the following approvals and authorizations: